Praxis Precision Medicines (PRAX) Stock Soars as Tremor Drug Clears Key Clinical Milestone

TLDR TD Cowen raised Praxis Precision Medicines price target from $61 to $251, maintaining a Buy rating after strong Phase 3 results Ulixacaltamide HCl met primary endpoints in both essential tremor studies, showing improved daily living activities and maintained treatment effects The stock has jumped over 92% in the past six months and surged 183.71% [...]

The post Praxis Precision Medicines (PRAX) Stock Soars as Tremor Drug Clears Key Clinical Milestone appeared first on Blockonomi.